| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy
|
Lv, Daojun
|
|
|
70 |
12 |
p. 3587-3602
|
artikel
|
| 2 |
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer
|
McGray, A. J. R.
|
|
|
70 |
12 |
p. 3451-3460
|
artikel
|
| 3 |
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
|
Chen, Xi
|
|
|
70 |
12 |
p. 3513-3524
|
artikel
|
| 4 |
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
|
Lu, Wenyi
|
|
|
70 |
12 |
p. 3501-3511
|
artikel
|
| 5 |
CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
|
Wu, Pin
|
|
|
70 |
12 |
p. 3603-3616
|
artikel
|
| 6 |
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
|
Reusing, Sarah B.
|
|
|
70 |
12 |
p. 3701-3708
|
artikel
|
| 7 |
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
|
Mair, Maximilian J.
|
|
|
70 |
12 |
p. 3643-3650
|
artikel
|
| 8 |
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
|
Hansen, Kyle
|
|
|
70 |
12 |
p. 3525-3540
|
artikel
|
| 9 |
Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
|
Salewski, Inken
|
|
|
70 |
12 |
p. 3405-3419
|
artikel
|
| 10 |
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma
|
Fan, Tao
|
|
|
70 |
12 |
p. 3651-3667
|
artikel
|
| 11 |
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
|
Reusing, Sarah B.
|
|
|
70 |
12 |
p. 3709
|
artikel
|
| 12 |
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
|
Hu, Hai-Jun
|
|
|
70 |
12 |
p. 3541-3555
|
artikel
|
| 13 |
Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients
|
Rodin, William
|
|
|
70 |
12 |
p. 3461-3475
|
artikel
|
| 14 |
Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice
|
Berriel, Edgardo
|
|
|
70 |
12 |
p. 3617-3627
|
artikel
|
| 15 |
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas
|
Oike, Naoki
|
|
|
70 |
12 |
p. 3489-3499
|
artikel
|
| 16 |
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors
|
Tasaki, Mamoru
|
|
|
70 |
12 |
p. 3557-3571
|
artikel
|
| 17 |
Immune infiltrate diversity confers a good prognosis in follicular lymphoma
|
Tsakiroglou, Anna-Maria
|
|
|
70 |
12 |
p. 3573-3585
|
artikel
|
| 18 |
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery
|
Kono, Michihisa
|
|
|
70 |
12 |
p. 3421-3434
|
artikel
|
| 19 |
Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity
|
Baecher, Kirsten M.
|
|
|
70 |
12 |
p. 3397-3404
|
artikel
|
| 20 |
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome
|
Kanie, Keitaro
|
|
|
70 |
12 |
p. 3669-3677
|
artikel
|
| 21 |
Megakaryoblastic leukemia: a study on novel role of clinically significant long non-coding RNA signatures in megakaryocyte development during treatment with phorbol ester
|
Dahariya, Swati
|
|
|
70 |
12 |
p. 3477-3488
|
artikel
|
| 22 |
Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism
|
Chen, Hui-Ming
|
|
|
70 |
12 |
p. 3435-3449
|
artikel
|
| 23 |
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
|
Khodayari, Hamid
|
|
|
70 |
12 |
p. 3369-3395
|
artikel
|
| 24 |
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial
|
Filaci, Gilberto
|
|
|
70 |
12 |
p. 3679-3692
|
artikel
|
| 25 |
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
|
Deronic, Adnan
|
|
|
70 |
12 |
p. 3629-3642
|
artikel
|
| 26 |
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
|
Braun, Christiane
|
|
|
70 |
12 |
p. 3693-3700
|
artikel
|
Tijdschrift beschrijving